ReviewJBMR plus2025
Periprosthetic inflammation: from the cellular level to clinical implications.
Review in JBMR plus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Key Inflammatory Pathways, Biomarkers, and Targeted Management Strategies in Primary Total Joint Arthroplasty: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Circulating monocytes from aseptic loosening patients exhibit enhanced tropism toward periprosthetic tissues in NOD-SCID mouse model.Scientific reports · 2026Article
- Osteoporosis and osteoporosis therapies as determinants of implant fixation failure in arthroplasty and spinal fusion constructs: a position statement from the Fracture Working Group of the Council of Scientific Advisors of the International Osteoporosis Foundation.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Laboratory biomarkers and radiographic osteolysis after total knee arthroplasty: a retrospective pilot study.Frontiers in surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Periprosthetic inflammation is a crucial factor contributing to aseptic loosening, the leading cause of implant failures. Metallic debris, including nanoparticles, sub-micron particles, and ions, plays a central role in triggering inflammatory responses around orthopedic implants. Exposure to the debris activates macrophages via toll-like receptors and nucleotide-binding and oligomerization domain-like receptors, which in turn leads to the production of pro-inflammatory cytokines. This signaling cascade subsequently drives osteoclast activation, resulting in periprosthetic bone loss and, ultimately, implant loosening. Recent research has focused on strategies to prevent aseptic loosening by targeting the inflammation induced by metallic particles/ions. Pharmacological interventions aimed at modulating macrophage activation and inhibiting specific inflammatory pathways have shown promise in reducing osteoclast activity and excessive bone resorption. This review provides a comprehensive overview of the processes involved in the pathogenesis of periprosthetic inflammation, beginning with the release of metallic debris and its recognition by immune cells, followed by the inflammatory reactions that lead to osteoclastogenesis and bone loss. A detailed understanding of these molecular mechanisms is essential for the development of targeted approaches to prevent aseptic loosening, improve long-term patient outcomes, and alleviate the economic burden on healthcare systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.